Related Experiment Videos

Percutaneous peripheral rotational ablation using the Rotablator: immediate and mid term results. Single center

M Henry1, M Amor, G Ethevenot

  • 1Cardiology and Surgical Intervention Unit, Polyclinic, Essey Les Nancy, France.

Insights

Percutaneous Peripheral Rotational Ablation (PPRA) effectively treats peripheral vascular lesions, especially in distal leg arteries, with high technical success and good long-term patency. Longer lesions (>7 cm) may present limitations for PPRA.

Area of Science:

  • Vascular Surgery
  • Interventional Cardiology
  • Endovascular Therapy

Background:

  • Peripheral vascular lesions (PVL) significantly impact patient mobility and quality of life.
  • Traditional treatments for PVL can be invasive with associated risks.
  • Rotablator (PPRA) offers a minimally invasive approach for PVL treatment.

Purpose of the Study:

  • To evaluate the efficacy and safety of Percutaneous Peripheral Rotational Ablation (PPRA) for treating symptomatic peripheral vascular lesions (PVL).
  • To assess the technical success, complication rates, and long-term outcomes of PPRA in a diverse patient cohort.
  • To identify factors influencing restenosis and determine optimal indications for PPRA.

Main Methods:

  • A prospective study involving 95 patients with 146 PVL treated with PPRA.
  • Lesions were categorized by location (above/below knee) and length, with runoff status documented.
  • Complementary percutaneous transluminal angioplasty (PTA) was utilized as needed, and outcomes were assessed via angiography.

Main Results:

  • PPRA achieved a high primary technical success rate of 97% per lesion and 95% per patient.
  • Mean stenosis decreased significantly from 81% to 18% post-PPRA alone.
  • Restenosis rates were higher for longer lesions (≥7 cm) and in femoral arteries, suggesting potential limitations.

Conclusions:

  • PPRA is a valuable tool for treating PVL, particularly in distal leg arteries, demonstrating high technical success.
  • The technique shows promise for complex vascular lesions and may improve long-term patency of PTA and bypass grafts.
  • Lesion length greater than or equal to 6.7 cm appears to be a limitation for PPRA, warranting further investigation.

Related Concept Videos